CRESCENT BIOPHARMA, INC. (CBIO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 18.54M USD | Liabilities, Current |
| Cash and equivalents | 171.59M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 0.00 USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $18.54M | $171.59M | (m) | $0.00 | (m) | (m) |
| 2026-03-31 | (m) | $14.19M | $189.16M | (m) | $0.00 | (m) | (m) |
| 2025-12-31 | (m) | $36.07M | $213.19M | (m) | $18.00M | (m) | (m) |
| 2025-09-30 | (m) | $20.30M | $133.26M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $16.75M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $2.62M | $5.61M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $5.78M | $10.72M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.32M | $14.39M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $4.36M | $22.39M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.29M | $31.28M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.84M | $41.79M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $6.39M | $49.41M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $6.57M | $58.04M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $6.74M | $65.00M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $8.88M | $47.87M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $7.75M | $51.62M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $8.94M | $60.24M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $12.78M | $76.52M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $11.82M | $90.25M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $9.66M | $101.92M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $10.25M | $118.85M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $10.84M | $132.47M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.43M | $137.04M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $9.82M | $142.87M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $9.70M | $149.84M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $10.61M | $154.82M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $10.95M | $158.20M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $10.44M | $170.89M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $10.63M | $184.17M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $8.31M | $195.56M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $8.76M | $209.92M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $6.43M | $219.83M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.04M | $229.43M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $8.70M | $242.63M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $8.17M | $123.92M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $6.53M | $112.87M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $5.45M | $119.15M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $4.53M | $34.59M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $6.33M | $40.04M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $5.42M | $45.28M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $6.09M | $53.09M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $5.68M | $38.83M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $7.75M | $46.80M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.85M | $53.76M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $6.80M | $40.23M | (m) | $20.00M | (m) | (m) |
| 2015-03-31 | (m) | $4.10M | $46.57M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $6.46M | $55.20M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $4.71M | $61.36M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $3.60M | $66.22M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $2.64M | $56.97M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.28M | $2.31M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $7.69M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $10.78M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $13.49M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $17.37M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $28.17M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |